Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance

(2018) Patrick N. A. Harris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

(2016) Boudewijn L. M. de Jonge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014

(2016) Sibylle H. Lob et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Differences in risk-factor profiles between patients with ESBL-producing Escherichia coli and Klebsiella pneumoniae: a multicentre case-case comparison study

(2014) Joshua T Freeman et al.   Antimicrobial Resistance and Infection Control

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study

(2013) G. G. Zhanel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular epidemiology of extended-spectrum  -lactamase-, AmpC  -lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11

(2013) A. J. Denisuik et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular Epidemiological Analysis of Escherichia coli Sequence Type ST131 (O25:H4) andblaCTX-M-15among Extended-Spectrum-β-Lactamase-Producing E. coli from the United States, 2000 to 2009

(2012) James R. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular epidemiology of extended-spectrum- -lactamase-producing Klebsiella pneumoniae over a 10 year period in Calgary, Canada

(2012) G. Peirano et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

(2012) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Carbapenems: Past, Present, and Future

(2011) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST expert rules in antimicrobial susceptibility testing

(2011) R. Leclercq et al.   CLINICAL MICROBIOLOGY AND INFECTION

Detection of AmpC Beta-Lactamase in Escherichia coli: Comparison of Three Phenotypic Confirmation Assays and Genetic Analysis

(2011) S. Peter-Getzlaff et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Molecular Epidemiology over an 11-Year Period (2000 to 2010) of Extended-Spectrum  -Lactamase-Producing Escherichia coli Causing Bacteremia in a Centralized Canadian Region

(2011) G. Peirano et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predominance of an ST11 extended-spectrum β-lactamase-producing Klebsiella pneumoniae clone causing bacteraemia and urinary tract infections in Korea

(2010) Kwan Soo Ko et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Characterization of Cefoxitin-Resistant Escherichia coli Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006

(2009) L. F. Mataseje et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AmpC  -Lactamases

(2009) G. A. Jacoby   CLINICAL MICROBIOLOGY REVIEWS